457 related articles for article (PubMed ID: 8174988)
1. Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide.
Lieverse RJ; Jansen JB; Masclee AA; Rovati LC; Lamers CB
Gut; 1994 Apr; 35(4):501-5. PubMed ID: 8174988
[TBL] [Abstract][Full Text] [Related]
2. Satiety effects of the type A CCK receptor antagonist loxiglumide in lean and obese women.
Lieverse RJ; Masclee AA; Jansen JB; Rovati LC; Lamers CB
Biol Psychiatry; 1995 Mar; 37(5):331-5. PubMed ID: 7748985
[TBL] [Abstract][Full Text] [Related]
3. Role of circulating cholecystokinin in control of fat-induced inhibition of food intake in humans.
Drewe J; Gadient A; Rovati LC; Beglinger C
Gastroenterology; 1992 May; 102(5):1654-9. PubMed ID: 1568575
[TBL] [Abstract][Full Text] [Related]
4. Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans.
Beglinger C; Degen L; Matzinger D; D'Amato M; Drewe J
Am J Physiol Regul Integr Comp Physiol; 2001 Apr; 280(4):R1149-54. PubMed ID: 11247838
[TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin receptor antagonist loxiglumide modulates plasma levels of gastro-entero-pancreatic hormones in man. Feedback control of cholecystokinin and gastrin secretion.
Schmidt WE; Creutzfeldt W; Höcker M; Nustede R; Choudhury AR; Schleser A; Rovati LC; Fölsch UR
Eur J Clin Invest; 1991 Oct; 21(5):501-11. PubMed ID: 1752290
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of food intake in response to intestinal lipid is mediated by cholecystokinin in humans.
Matzinger D; Gutzwiller JP; Drewe J; Orban A; Engel R; D'Amato M; Rovati L; Beglinger C
Am J Physiol; 1999 Dec; 277(6):R1718-24. PubMed ID: 10600919
[TBL] [Abstract][Full Text] [Related]
7. The role of long chain fatty acids in regulating food intake and cholecystokinin release in humans.
Matzinger D; Degen L; Drewe J; Meuli J; Duebendorfer R; Ruckstuhl N; D'Amato M; Rovati L; Beglinger C
Gut; 2000 May; 46(5):688-693. PubMed ID: 10764713
[TBL] [Abstract][Full Text] [Related]
8. Effects of somatostatin and loxiglumide on gallbladder motility.
Lieverse RJ; Jansen JB; Jebbink MC; Masclee AA; Rovati LC; Lamers CB
Eur J Clin Pharmacol; 1995; 47(6):489-92. PubMed ID: 7768249
[TBL] [Abstract][Full Text] [Related]
9. Role of endogenously released cholecystokinin in determining postprandial insulin levels in man: effects of loxiglumide, a specific cholecystokinin receptor antagonist.
Baum F; Nauck MA; Ebert R; Cantor P; Hoffmann G; Choudhury AR; Schmidt WE; Creutzfeldt W
Digestion; 1992; 53(3-4):189-99. PubMed ID: 1291406
[TBL] [Abstract][Full Text] [Related]
10. The effects of loxiglumide on food intake in normal weight volunteers.
French SJ; Bergin A; Sepple CP; Read NW; Rovati L
Int J Obes Relat Metab Disord; 1994 Nov; 18(11):738-41. PubMed ID: 7866473
[TBL] [Abstract][Full Text] [Related]
11. Effects of cholecystokinin receptor blockade on circulating concentrations of glucose, insulin, C-peptide, and pancreatic polypeptide after various meals in healthy human volunteers.
Niederau C; Schwarzendrube J; Lüthen R; Niederau M; Strohmeyer G; Rovati L
Pancreas; 1992; 7(1):1-10. PubMed ID: 1557335
[TBL] [Abstract][Full Text] [Related]
12. Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans.
Hildebrand P; Ensinck JW; Ketterer S; Delco F; Mossi S; Bangerter U; Beglinger C
J Clin Endocrinol Metab; 1991 May; 72(5):1123-9. PubMed ID: 2022712
[TBL] [Abstract][Full Text] [Related]
13. Cholecystokinin receptor antagonist loxiglumide: influence on bilio-pancreatic secretion and gastrointestinal hormones in man.
Schmidt WE; Creutzfeldt W; Höcker M; Choudhury AR; Nustede R; Schleser A; Nitsche R; Rovati LC; Schafmayer A; Fölsch UR
Digestion; 1990; 46 Suppl 2():232-9. PubMed ID: 2262057
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of intraduodenal infusion of loxiglumide on pancreatic exocrine secretion.
Tanikawa M; Hayakawa T; Kondo T; Shibata T; Kitagawa M; Kodaira T; Hamaoka T
Arzneimittelforschung; 1993 Jan; 43(1):35-9. PubMed ID: 8447844
[TBL] [Abstract][Full Text] [Related]
15. Comparison of loxiglumide, a cholecystokinin receptor antagonist, and atropine on hormonal and meal-stimulated pancreatic secretion in man.
Gabryelewicz A; Kulesza E; Konturek SJ
Scand J Gastroenterol; 1990 Jul; 25(7):731-8. PubMed ID: 2396088
[TBL] [Abstract][Full Text] [Related]
16. Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.
Konturek JW
J Physiol Pharmacol; 1994 Dec; 45(4 Suppl 1):3-66. PubMed ID: 7787215
[TBL] [Abstract][Full Text] [Related]
17. Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide.
Fried M; Erlacher U; Schwizer W; Löchner C; Koerfer J; Beglinger C; Jansen JB; Lamers CB; Harder F; Bischof-Delaloye A
Gastroenterology; 1991 Aug; 101(2):503-11. PubMed ID: 2065926
[TBL] [Abstract][Full Text] [Related]
18. Role of CCK in regulation of pancreaticobiliary functions and GI motility in humans: effects of loxiglumide.
Schmidt WE; Creutzfeldt W; Schleser A; Choudhury AR; Nustede R; Höcker M; Nitsche R; Sostmann H; Rovati LC; Fölsch UR
Am J Physiol; 1991 Feb; 260(2 Pt 1):G197-206. PubMed ID: 1996640
[TBL] [Abstract][Full Text] [Related]
19. Interaction between CCK and a preload on reduction of food intake is mediated by CCK-A receptors in humans.
Gutzwiller JP; Drewe J; Ketterer S; Hildebrand P; Krautheim A; Beglinger C
Am J Physiol Regul Integr Comp Physiol; 2000 Jul; 279(1):R189-95. PubMed ID: 10896881
[TBL] [Abstract][Full Text] [Related]
20. Bombesin reduces food intake in lean man by a cholecystokinin-independent mechanism.
Lieverse RJ; Jansen JB; van de Zwan A; Samson L; Masclee AA; Rovati LC; Lamers CB
J Clin Endocrinol Metab; 1993 Jun; 76(6):1495-8. PubMed ID: 8501156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
